Skip to main content
. 2021 Apr 25;70(12):3501–3511. doi: 10.1007/s00262-021-02941-4

Fig. 1.

Fig. 1

The probability of two-year overall survival and event-free survival in MRD-positive patients and the patients with active disease treated after CAR-T cell therapy. a The probability of two-year overall survival after CAR-T cell therapy; b The probability of two-year event-free survival after CAR-T cell therapy